Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)

Ítems similars

• Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)
  per: Bruce K. Patterson, et al.
  Publicat: (2024-05-01)
• Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection
  per: Bruce K. Patterson, et al.
  Publicat: (2022-01-01)
• Correction: Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection
  per: Bruce K. Patterson, et al.
  Publicat: (2026-04-01)
• Perioperative and anesthetic considerations for post-acute sequelae of COVID (PASC)/long COVID
  per: Ram Yogendra, et al.
  Publicat: (2025-07-01)
• Maraviroc attenuates orbital remodeling, inflammation, and lipid dysregulation in a murine model of thyroid eye disease associated with Graves’ disease
  per: Fahimeh Hashemi Arani, et al.
  Publicat: (2026-02-01)